Director Tomas Kiselak resigns; Sujay Kango appointed to board and compensation committee

Dianthus Therapeutics, Inc. /DE/

Tomas Kiselak resigned from Dianthus Therapeutics board effective March 4, 2025; no disagreement cited.
Sujay Kango appointed as Class II director and member of Compensation Committee, effective March 4, 2025.
Kango receives initial option grant of 25,000 shares vesting over three years; cash compensation of $40,000/yr (board) and $6,000/yr (committee).
Kango will enter into a standard indemnification agreement with the company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Sujay Kango

Director

DNTH · Dianthus Therapeutics, Inc. /DE/

Effective: 2025-03-04
Filed: March 5, 2025, 6:59 PM ET

On March 4, 2025, the Board appointed Sujay Kango as a Class II director of the Company and as a member of the Compensation Committee of the Board (the “Compensation Committee”), effective immediately after close of business on March 4, 2025.

Departed

Tomas Kiselak

Director

DNTH · Dianthus Therapeutics, Inc. /DE/

Effective: 2025-03-04
Successor: Sujay Kango
Filed: March 5, 2025, 6:59 PM ET

On March 4, 2025, Tomas Kiselak, a member of the Board of Directors (the “Board) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective as of the close of business on March 4, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Sujay Kango was appointed as Director at Dianthus Therapeutics, Inc. /DE/.

Action: appointed
Role: Director

Exact text from the filing

On March 4, 2025, the Board appointed Sujay Kango as a Class II director of the Company and as a member of the Compensation Committee of the Board (the “Compensation Committee”), effective immediately after close of business on March 4, 2025.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Tomas Kiselak resigned as Director at Dianthus Therapeutics, Inc. /DE/.

Action: resigned
Role: Director

Exact text from the filing

On March 4, 2025, Tomas Kiselak, a member of the Board of Directors (the “Board) of Dianthus Therapeutics, Inc. (the “Company”), notified the Company of his resignation from the Board effective as of the close of business on March 4, 2025.

View on SEC.gov

Dianthus Therapeutics, Inc. /DE/ filing history →

Source: SEC EDGAR

accession 0000950170-25-033075

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.